Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database

• Main Authors: Rachel Prevost (Author), Basile Chretien (Author), Elise-Marie Minoc (Author), Charles Dolladille (Author), Angélique Da-Silva (Author), Ahmad Nehme (Author), Florence Joly (Author), Véronique Lelong-Boulouard (Author), Etienne Bastien (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Importance: Endocrine therapies (ETs) and inhibitors of cyclin-dependent kinases-4/6 (iCDK4/6s) are a standard treatment in breast cancer. However, data on potential neurocognitive impacts remain inconsistent for ET and are scarce for iCDK4/6s.Objective: To evaluate whether ET and iCDK4/6s are assoc...